Full-Year Financial Results Presentation Materials for the Fiscal Year Ending March 2026 (54th Fiscal Period) | Japan Medical Dynamic Marketing,INC. (7600) timely disclosure

Worth reading

58In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Deterioration

Direction inferred from the company’s description.

Scale

-981

¥ millions (year-on-year change in operating income)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ending March 2026, full year10 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥23,917 million-4.8%

Operating profit¥574 million-63.1%

Ordinary income¥534 million-64.1%

Net income¥263 million

Operating profit margin2.4 %

Selling, general and administrative expenses¥13,567 million

Full-year earnings forecast

Net Sales

¥25,370 million

Operating profit

¥430 million

Ordinary income

¥140 million

Net income for the current fiscal year

¥60 million

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Gross profit contraction due to lower revenue¥-12 100 million
Deterioration in manufacturing costs¥-2.6 100 million
SG&A expense control¥4.3 100 million
Year-on-year change in operating profit¥-9.8 100 million
Impact of US reciprocal tariffs¥69 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Assumed Exchange Rates¥155.0/US dollar

Foreign exchange sensitivityOperating profit: ¥30 million per ¥1 change in the exchange rate

Impact of reimbursement price reductionsExpected deterioration of ¥50 million (0.4%) year on year

Cost-of-sales ratio41％

US reciprocal tariffsUS$1.5M impact

New initiatives

Nationwide rollout of Trivicta Hip Stem and additional investment
Obtaining regulatory approval and launching 2 products related to artificial joints
Obtaining regulatory approval for Chinese-made artificial hip joints and commencing local production
In-house production and procurement-source diversification through the SAICO project
Supply agreements with major suppliers and strengthened supplier management
KIZUNA corporate culture reform project
Preparation for an application to list on the Standard Market of the Tokyo Stock Exchange

Key KPIsA metric the company considers important as a management benchmark.

GHG emissions (Scope 1 + 2)1,444 t
Year on year against the same period last yearReduced by 525t (27%) from the fiscal year ending March 2020
CDP climate change assessmentB
Year on year against the same period last yearUnchanged from the previous year
CDP water security assessmentB-
Number of products launched0 Engagements
Number of educational programs conducted2 Engagements
ISO 13485 maintenance audit findings0 Engagements

Segment results

Domestic sales in Japan

¥13,109 million-3.8%

US sales

¥10,807 million-5.9%

Japan: artificial joints

¥4,904 million-6.4%

Japan: osteosynthesis materials

¥4,444 million-4.5%

Japan: spinal fixation devices

¥3,493 million-1.4%

US: artificial joints

¥10,774 million-5.9%

Medium-term management plan targets

Plan nameRolling Plan 2029

Fiscal year ending March 2028

Net Sales27,500

Operating profit1,000

Net income for the current fiscal year500

ROE2.0%

ROIC2.2%

Fiscal year ending March 2029

Net Sales30,000

Operating profit1,500

Net income for the current fiscal year1,000

ROE3.9%

ROIC3.3%

Financial targets

ROE

Actual results for the fiscal year ending March 20261.1%

Target for the fiscal year ending March 20293.9%

ROIC

Actual results for the fiscal year ending March 20261.3%

Target for the fiscal year ending March 20293.3%

Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.

US reciprocal tariffsUS$1.5M (actual impact in the fiscal year ending March 2026: US$463 thousand, ¥69 million)

Capital expenditures

¥1,940 million forecast for the fiscal year ending March 2027

Payout ratio

At least 30% (stable dividends)

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Fiscal year ending March 2026, full year
Net Sales	¥23,917 million (YoY -4.8%)
Operating profit	¥574 million (YoY -63.1%)
Ordinary income	¥534 million (YoY -64.1%)
Net income	¥263 million
Operating profit margin	2.4 %
Selling, general and administrative expenses	¥13,567 million
Full-year earnings forecast	Net Sales ¥25,370 million / Operating profit ¥430 million / Ordinary income ¥140 million / Net income for the current fiscal year ¥60 million
Segment results	Domestic sales in Japan ¥13,109 million (YoY -3.8%) / US sales ¥10,807 million (YoY -5.9%) / Japan: artificial joints ¥4,904 million (YoY -6.4%) / Japan: osteosynthesis materials ¥4,444 million (YoY -4.5%) / Japan: spinal fixation devices ¥3,493 million (YoY -1.4%) / US: artificial joints ¥10,774 million (YoY -5.9%)
Breakdown of Factors Affecting the Change	Factors Gross profit contraction due to lower revenue / Amount ¥-12 100 million, Factors Deterioration in manufacturing costs / Amount ¥-2.6 100 million, Factors SG&A expense control / Amount ¥4.3 100 million, Factors Year-on-year change in operating profit / Amount ¥-9.8 100 million, Factors Impact of US reciprocal tariffs / Amount ¥69 million
Key KPIs	Indicator name GHG emissions (Scope 1 + 2) / Value 1,444 t / Year on year against the same period last year Reduced by 525t (27%) from the fiscal year ending March 2020, Indicator name CDP climate change assessment / Value B / Year on year against the same period last year Unchanged from the previous year, Indicator name CDP water security assessment / Value B- / Year on year against the same period last year Not disclosed, Indicator name Number of products launched / Value 0 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of educational programs conducted / Value 2 Engagements / Year on year against the same period last year Not disclosed, Indicator name ISO 13485 maintenance audit findings / Value 0 Engagements / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business Outlook	Assumed Exchange Rates ¥155.0/US dollar / Foreign exchange sensitivity Operating profit: ¥30 million per ¥1 change in the exchange rate / Impact of reimbursement price reductions Expected deterioration of ¥50 million (0.4%) year on year / Cost-of-sales ratio 41％ / US reciprocal tariffs US$1.5M impact
Risk amount incorporated into the outlook	US reciprocal tariffs US$1.5M (actual impact in the fiscal year ending March 2026: US$463 thousand, ¥69 million)
Medium-term management plan targets	Plan name Rolling Plan 2029 / Fiscal year ending March 2028 Net Sales 27,500 / Operating profit 1,000 / Net income for the current fiscal year 500 / ROE 2.0% / ROIC 2.2% / Fiscal year ending March 2029 Net Sales 30,000 / Operating profit 1,500 / Net income for the current fiscal year 1,000 / ROE 3.9% / ROIC 3.3%
Financial targets	ROE Actual results for the fiscal year ending March 2026 1.1% / Target for the fiscal year ending March 2029 3.9% / ROIC Actual results for the fiscal year ending March 2026 1.3% / Target for the fiscal year ending March 2029 3.3%
Payout ratio	At least 30% (stable dividends)
Capital expenditures	¥1,940 million (forecast for the fiscal year ending March 2027)
New initiatives	Nationwide rollout of Trivicta Hip Stem and additional investment, Obtaining regulatory approval and launching 2 products related to artificial joints, Obtaining regulatory approval for Chinese-made artificial hip joints and commencing local production, In-house production and procurement-source diversification through the SAICO project, Supply agreements with major suppliers and strengthened supplier management, KIZUNA corporate culture reform project, Preparation for an application to list on the Standard Market of the Tokyo Stock Exchange

Items this document does not state (12)

Gross Profit MarginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAnnual DividendAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The factors cited include lower sales in Japan and the US, a decline in the number of cases acquired due to reported incidents and supply constraints, higher labor, manufacturing overhead and procurement costs, and the impact of US reciprocal tariffs. Meanwhile, cost-control initiatives improved selling, general and administrative expenses by ¥430 million from the previous fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.